Neuropsychiatric side effects of interferon-alfa therapy

被引:39
作者
Van Gool, AR [1 ]
Kruit, WHJ
Engels, FK
Stoter, G
Bannink, M
Eggermont, AMM
机构
[1] Erasmus Univ, Med Ctr, Dr Daniel den Hoed Canc Ctr, Dept Psychosocial Oncol, Rotterdam, Netherlands
[2] Erasmus Univ, Med Ctr, Dr Daniel den Hoed Canc Ctr, Dept Med Oncol, Rotterdam, Netherlands
[3] Erasmus Univ, Med Ctr, Dept Pharm, Rotterdam, Netherlands
[4] Erasmus Univ, Med Ctr, Dr Daniel den Hoed Canc Ctr, Dept Surg Oncol, Rotterdam, Netherlands
来源
PHARMACY WORLD & SCIENCE | 2003年 / 25卷 / 01期
关键词
adverse drug reaction; depression; interferon; neuropsychiatric; side effect;
D O I
10.1023/A:1022449613907
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Aim: Immunotherapy with interferon-alfa (IFN-alfa) is used in a variety of diseases in- and outside clinical trials (e. g. chronic hepatitis, melanoma, chronic myelogenous leukemia, renal cell carcinoma, multiple myeloma). Treatment with IFN-alfa can cause (severe) neuropsychiatric side effects. The purpose of this article is to give an updated review of data on the incidence, manifestations and prediction of psychiatric side effects of immunotherapy with IFN-alfa. Furthermore, the article gives an overview of the management strategies and of the various theories on the pathophysiology of behavioural effects induced by cytokines. Methods: Use was made of computerized searches and of checking cross-references of articles and book chapters. The data on the incidence, manifestations and prediction are arranged by source of information, by target symptoms and by method of ascertainment. Results: Different sources of information exist, e. g. adverse event reports of clinical trials, case descriptions and research specifically targeted on neuropsychiatric side effects. IFN-alfa is capable of inducing depressive symptoms and syndromes; the evidence for the induction of other psychiatric side effects is weaker. The depressive syndromes induced by IFN-alfa are in need of a more precise characterization. The results of studies on prediction of side effects are contradictory. Guidelines on managing psychiatric side effects predominantly arise from practical experience and common sense. Patient education plays a pivotal role. At this moment, there is no comprehensive theory on the pathophysiology of cytokine-induced psychiatric side effects. Conclusion: There is sufficient empirical support for a causal relation between IFN-alfa and the development of depressive symptoms and syndromes. Practical management of neuropsychiatric side effects begins before the start of therapy and should consist of repeated patient education, drug treatment and supportive measures. There are diverging theories on the pathophysiological backgrounds.
引用
收藏
页码:11 / 20
页数:10
相关论文
共 59 条
[1]
NEUROPSYCHIATRIC MANIFESTATIONS OF HUMAN-LEUKOCYTE INTERFERON THERAPY IN PATIENTS WITH CANCER [J].
ADAMS, F ;
QUESADA, JR ;
GUTTERMAN, JU .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (07) :938-941
[2]
ADAMS F, 1988, J NEURO-ONCOL, V6, P355
[3]
Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system [J].
Bonaccorso, S ;
Marino, V ;
Puzella, A ;
Pasquini, M ;
Biondi, M ;
Artini, M ;
Almerighi, C ;
Verkerk, R ;
Meltzer, H ;
Maes, M .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2002, 22 (01) :86-90
[4]
Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms [J].
Bonaccorso, S ;
Puzella, A ;
Marino, V ;
Pasquini, M ;
Biondi, M ;
Artini, M ;
Almerighi, C ;
Levrero, M ;
Egyed, B ;
Bosmans, E ;
Meltzer, HY ;
Maes, M .
PSYCHIATRY RESEARCH, 2001, 105 (1-2) :45-55
[5]
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy [J].
Capuron, L ;
Ravaud, A ;
Neveu, PJ ;
Miller, AH ;
Maes, M ;
Dantzer, R .
MOLECULAR PSYCHIATRY, 2002, 7 (05) :468-473
[6]
Neurobehavioral effects of interferon-α in cancer patients:: Phenomenology and paroxetine responsiveness of symptom dimensions [J].
Capuron, L ;
Gumnick, JF ;
Musselman, DL ;
Lawson, DH ;
Reemsnyder, A ;
Nemeroff, CB ;
Miller, AH .
NEUROPSYCHOPHARMACOLOGY, 2002, 26 (05) :643-652
[7]
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-α treatments in cancer patients [J].
Capuron, L ;
Ravaud, A ;
Dantzer, R .
PSYCHOSOMATIC MEDICINE, 2001, 63 (03) :376-386
[8]
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state [J].
Capuron, L ;
Ravaud, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (17) :1370-1370
[9]
Caraceni A, 1998, CANCER, V83, P482, DOI 10.1002/(SICI)1097-0142(19980801)83:3<482::AID-CNCR17>3.0.CO
[10]
2-S